- Home
- PROK vs FINS Comparison
PROK vs FINS Comparison
Compare PROK & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROK | FINS |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 429.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PROK | FINS |
|---|---|---|
| Price | $2.26 | $13.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 78.0K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.97% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $744,000.00 | N/A |
| Revenue This Year | $918.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $11.61 |
| 52 Week High | $7.13 | $12.57 |
Technical Indicators
Market Signals| Indicator | PROK | FINS |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 58.50 |
| Support Level | $2.04 | $12.81 |
| Resistance Level | $2.25 | $13.10 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 26.19 | 88.17 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.